Your Nose and Your Lungs Are More Connected Than You Think

Your nose is not an island

If you've ever noticed that your hayfever season seems to bring more than just a runny nose — that your chest feels tighter, your eyes stream independently of your sneezes, or that you carry a persistent sinus pressure that lingers long after the pollen count drops — you're not imagining it. Your body isn't giving you several separate problems. It's showing you one.

The science of allergic disease has undergone a quiet revolution over the past two decades. What was once understood as a collection of unrelated conditions — hayfever here, asthma there, eczema somewhere else — is now recognised as a deeply interconnected system of inflammation, sharing the same biological roots, the same immune pathways, and often the same trajectory through a person's life. Understanding this changes not just how you think about your hayfever, but how proactively you can protect your health over years and decades.

---

The science: one airway, one disease

The numbers that tell a story

The epidemiology alone is striking. Among people with allergic rhinitis, somewhere between 10% and 40% also have asthma. But flip the relationship around and the picture is even more dramatic: between 40% and 90% of asthma patients have comorbid allergic rhinitis (Gaugris et al., 2006; Shen et al., 2019). A large meta-analysis of Chinese populations found a 10.17% prevalence of asthma in rhinitis patients, versus a 38.97% prevalence of rhinitis in asthma patients — confirming that if you have asthma, your airways are almost certainly already involved in a broader allergic process (Shen et al., 2019). US national health survey data (NHIS 2021) shows over 80% of adults with asthma report allergy-related nasal symptoms.

This isn't coincidence. It's biology.

The united airway hypothesis

The term 'united airway disease' — sometimes called 'one airway, one disease' — describes what immunologists now understand: that allergic rhinitis and asthma are not two conditions that happen to coexist, but two expressions of the same underlying inflammatory process playing out across connected mucosal tissue (Ozdoganoglu & Songu, 2012).

Both conditions are driven by Th2-mediated immune responses: your immune system encounters an allergen (grass pollen, house dust mite, tree pollen) and mounts an IgE-mediated reaction involving mast cell degranulation, eosinophil infiltration, and the release of cytokines — particularly IL-4, IL-5, and IL-13. These are the molecules that cause the swelling, mucus, and hypersensitivity characteristic of both hayfever and asthma. The difference is location: in rhinitis, this happens in the nasal mucosa; in asthma, it happens in the bronchial lining. But the lining is continuous. The inflammation doesn't respect the anatomical boundary between nose and lung.

There's also a mechanical dimension: post-nasal drip can directly trigger vagal reflexes that cause bronchoconstriction, and allergen-driven inflammation in the nose appears capable of spreading systemically to prime bronchial tissue for reactivity, even when no allergen has directly reached the lungs.

The atopic march: how it starts in childhood

For many people, this interconnected story begins earlier than their first hayfever season. The 'atopic march' describes a well-documented — if not perfectly linear — progression: eczema in infancy, followed by allergic rhinitis and then asthma in childhood or early adulthood (Spergel, 2010).

The mechanism begins in the skin. Mutations in the filaggrin gene weaken the skin barrier, allowing allergens to penetrate and drive a Th2-skewed immune response before the airways have ever been directly exposed. IgE production, eosinophilia, and systemic cytokine signalling then predispose the nasal and bronchial mucosa to later allergic inflammation. Children with eczema who are also allergen-sensitised show substantially higher rates of progression to respiratory atopic disease than those without sensitisation (Martin et al., 2011).

Longitudinal birth cohort studies consistently show that childhood eczema predicts atopic asthma specifically — not non-atopic asthma — with affected children carrying roughly a 50% risk of developing asthma (Owens et al., 2018). Importantly, rhinitis diagnosis frequently precedes asthma onset, making untreated hayfever in young people not just an inconvenience but a potential risk factor for lower airway disease.

When your sinuses join the conversation

The united airway extends upward as well as downward. Chronic rhinosinusitis (CRS) — persistent inflammation of the sinus cavities — is present in approximately 34% of adult CRS patients with concurrent allergy, rising to 53% in paediatric populations (Grimm et al., 2022; Tantilipikorn et al., 2020). Specific subtypes of CRS, particularly central compartment atopic disease (CCAD) and allergic fungal rhinosinusitis (AFRS), have the strongest allergic overlap.

Comorbid allergic rhinitis makes CRS harder to treat, more likely to recur after surgery, and is associated with higher rates of asthma, greater healthcare utilisation, and elevated risks of anxiety and depression (Choi et al., 2024). Both conditions share type 2 eosinophilic inflammatory pathways and respond to the same class of biologic therapies, reinforcing that their overlap is mechanistic, not merely incidental (Rosati & Peters, 2016).

Eyes: the forgotten frontier

Almost half of all hayfever sufferers also experience allergic conjunctivitis — itchy, watery, red eyes driven by the same IgE-mediated mast cell activation occurring in the nose (Iordache et al., 2022). The conjunctival tissue is directly exposed to airborne allergens and has its own local immunological dynamics, meaning that systemic antihistamines or intranasal steroids — while helpful — often don't fully resolve ocular symptoms.

A proposed nasal-ocular reflex may also link the two: nasal allergen exposure can trigger reflex tearing and conjunctival irritation even before direct ocular allergen contact (Borges et al., 2025). Topical ophthalmic antihistamines and mast cell stabilisers target this tissue-specific inflammatory cascade more directly and are considered an important adjunct for patients with significant eye involvement.

---

What this means for you

If your hayfever feels like it's doing more than irritating your nose, this science gives you a framework for understanding why. Your symptoms aren't a collection of separate bad luck — they're your immune system expressing a unified pattern of sensitivity across connected tissue.

This also means that how well you manage your rhinitis has implications beyond comfort during peak season. Poorly controlled allergic rhinitis is an independent risk factor for developing asthma (Morjaria et al., 2018). If you had eczema as a child, your atopic trajectory may already be in motion. If your sinuses are chronically congested, allergy may be a significant driver. If your eyes are streaming on high-pollen days, they deserve targeted attention — not just as a side effect of hayfever, but as part of the same inflammatory picture.

---

The evidence landscape: what we know and what we don't

The united airway hypothesis is well-supported by decades of mechanistic and epidemiological research, and the association between allergic rhinitis and asthma is one of the most robust findings in allergy medicine. The atopic march is consistently observed in longitudinal birth cohort studies, and the sinusitis-rhinitis overlap has strong biological plausibility.

However, some important caveats are worth being honest about:

On prevalence figures: The 10–40% range for asthma comorbidity in rhinitis patients reflects genuine variability — specialist clinic populations show higher rates than general population surveys, and methodology differences make direct comparison difficult (Gaugris et al., 2006).

On the atopic march: The progression is not universal or strictly sequential. Many children with eczema never develop hayfever or asthma. Co-occurrence may partly reflect shared genetic predisposition and early environmental exposures rather than true step-by-step causation, as sibling and twin study analyses suggest (Hopper et al., 2012). The march is a useful framework, not a guaranteed script.

On treatment preventing asthma: This is where the evidence is most genuinely uncertain. Allergen immunotherapy (AIT) has the strongest case for potentially modifying disease progression and may interrupt the rhinitis-to-asthma trajectory by inducing immunological tolerance — but large, long-term randomised controlled trials measuring asthma incidence as a primary outcome are still lacking (Morjaria et al., 2018; Morjaria et al., 2014). Intranasal corticosteroids and antihistamines clearly improve asthma control in people who already have both conditions, but their role in preventing new-onset asthma is not established.

On sinusitis: Whether allergic rhinitis actively causes CRS, or whether both conditions independently arise from shared inflammatory terrain, remains unresolved.

---

What Haelo recommends

1. Don't treat your nose in isolation. If you have hayfever, ask yourself honestly: do you also notice chest tightness, wheezing, or breathlessness during peak pollen periods? These symptoms deserve clinical attention — mention them to your GP rather than attributing them solely to poor fitness or a seasonal cold.

2. If you have childhood eczema in your history, be alert. The atopic march means your respiratory system may be primed for allergic inflammation. This doesn't mean asthma is inevitable, but it means proactive, well-controlled rhinitis management is genuinely worthwhile — not just for comfort, but for long-term airway health.

3. Consider allergen immunotherapy if your hayfever is persistent and significant. AIT is the only treatment with plausible disease-modifying potential — addressing the root immunological cause rather than suppressing symptoms season by season. It requires commitment (typically 3 years), but the evidence for long-term benefit, including possible asthma risk reduction, is the strongest available (Morjaria et al., 2014).

4. Give your sinuses the attention they deserve. If you regularly experience facial pressure, post-nasal drip, or congestion that doesn't fully clear between seasons, discuss this with a clinician. CRS with an allergic component may need targeted allergy management — not just decongestants.

5. Treat your eyes as a distinct target, not an afterthought. Oral antihistamines provide partial ocular relief, but if your eye symptoms are significant, topical ophthalmic antihistamine drops (available over the counter) offer faster and more direct relief. Mast cell stabiliser drops, used before the season starts, can also help reduce baseline conjunctival reactivity.

6. Use your symptom tracking to see the whole picture. Haelo tracks your daily symptom experience alongside environmental data. If you notice chest symptoms rising with pollen counts, or eye symptoms that outpace your nasal ones, that's intelligence — use it in conversations with your healthcare team.

Your hayfever is telling you something about your whole immune system. The more clearly you can hear it, the better placed you are to respond — not just this season, but every season ahead.